JP2019520550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520550A5 JP2019520550A5 JP2018555652A JP2018555652A JP2019520550A5 JP 2019520550 A5 JP2019520550 A5 JP 2019520550A5 JP 2018555652 A JP2018555652 A JP 2018555652A JP 2018555652 A JP2018555652 A JP 2018555652A JP 2019520550 A5 JP2019520550 A5 JP 2019520550A5
- Authority
- JP
- Japan
- Prior art keywords
- dpp3
- pharmaceutical composition
- inhibitor
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110620A JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
| JP2024178873A JP2025011237A (ja) | 2016-04-21 | 2024-10-11 | Ｄｐｐ３の定量方法および治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16166476.8 | 2016-04-21 | ||
| EP16166476 | 2016-04-21 | ||
| PCT/EP2017/059377 WO2017182561A1 (en) | 2016-04-21 | 2017-04-20 | Methods for determining dpp3 and therapeutic methods |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076521A Division JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Division JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520550A JP2019520550A (ja) | 2019-07-18 |
| JP2019520550A5 true JP2019520550A5 (enExample) | 2020-05-28 |
Family
ID=56014788
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555652A Pending JP2019520550A (ja) | 2016-04-21 | 2017-04-20 | Ｄｐｐ３の定量方法および治療方法 |
| JP2020076521A Active JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Pending JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
| JP2024178873A Pending JP2025011237A (ja) | 2016-04-21 | 2024-10-11 | Ｄｐｐ３の定量方法および治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076521A Active JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Pending JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
| JP2024178873A Pending JP2025011237A (ja) | 2016-04-21 | 2024-10-11 | Ｄｐｐ３の定量方法および治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190145981A1 (enExample) |
| EP (5) | EP3896450A1 (enExample) |
| JP (4) | JP2019520550A (enExample) |
| KR (3) | KR102886883B1 (enExample) |
| CN (3) | CN110168372A (enExample) |
| AU (2) | AU2017252212B2 (enExample) |
| BR (1) | BR112018071583A2 (enExample) |
| CA (2) | CA3264486A1 (enExample) |
| CH (1) | CH713803B1 (enExample) |
| DE (1) | DE112017002105T5 (enExample) |
| IL (1) | IL262472B2 (enExample) |
| MX (3) | MX2018012856A (enExample) |
| MY (1) | MY200300A (enExample) |
| SG (1) | SG11201809252YA (enExample) |
| WO (1) | WO2017182561A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200300A (en) * | 2016-04-21 | 2023-12-19 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and therapeutic methods |
| EP3700937A2 (en) * | 2017-10-25 | 2020-09-02 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| US20220211798A1 (en) * | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| JP2022546061A (ja) * | 2019-08-30 | 2022-11-02 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ショック症治療のための治療法の誘導および／または治療法の監視 |
| US20230104578A1 (en) * | 2020-02-27 | 2023-04-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| BR112022015215A2 (pt) * | 2020-02-27 | 2022-10-11 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque |
| US20230250166A1 (en) | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| CN115769076A (zh) * | 2020-03-16 | 2023-03-07 | 4Teen4制药有限公司 | 感染冠状病毒的患者中的dpp3 |
| EP3922993A1 (en) * | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| CA3254142A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT |
| CN117186177B (zh) * | 2022-05-31 | 2024-08-23 | 中国农业大学 | 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法 |
| IL318667A (en) | 2022-07-29 | 2025-03-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| AU2023315168A1 (en) | 2022-07-29 | 2025-02-13 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| EP4633659A1 (en) | 2022-12-15 | 2025-10-22 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| CN115804836A (zh) * | 2022-12-27 | 2023-03-17 | 中国人民解放军海军特色医学中心 | 一种中枢小分子蛋白dpp3在制备降压药物中的应用 |
| JP2026513177A (ja) | 2023-03-29 | 2026-04-23 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤 |
| WO2026046947A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Anti-dpp3 antibody directed to and binding to dpp3 for the treatment of shock in extreme-critically ill patients |
| WO2026046968A1 (en) | 2024-08-26 | 2026-03-05 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binders for the treatment of endothelial dysfunction |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6188884A (ja) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06219989A (ja) * | 1993-01-27 | 1994-08-09 | Microbial Chem Res Found | 新規生理活性物質フルオスタチンａおよびｂ、その製造法およびその用途 |
| GB9312324D0 (en) * | 1993-06-15 | 1993-07-28 | Pitman Moore Inc | Vaccine |
| US5612186A (en) | 1994-06-22 | 1997-03-18 | Food Industry Research And Development Institute | Enzyme-capture assay (ECA) for the identification of Escherichia coli in clinical samples |
| US5601986A (en) | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1212434A2 (en) | 1999-09-01 | 2002-06-12 | Incyte Genomics, Inc. | Human hydrolytic enzymes |
| US6864363B2 (en) * | 2000-11-08 | 2005-03-08 | University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
| BR0212256A (pt) | 2001-08-30 | 2004-08-31 | Biorexis Pharmaceutical Corp | Proteìnas de fusão de transferrina modificadas |
| DK2311432T3 (en) | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2005106486A2 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) |
| WO2005118842A1 (ja) * | 2004-06-01 | 2005-12-15 | Sysmex Corporation | 酵素活性測定方法および酵素活性測定用カラム |
| WO2006032436A2 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag. | Use of microproteins as tryptase inhibitors |
| JP2006230318A (ja) | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | 関節リウマチの診断方法 |
| CN100420947C (zh) * | 2005-05-30 | 2008-09-24 | 孙东旭 | 用单一捕获剂定量检测特异性分析物的方法及其试剂盒 |
| US20070148130A1 (en) * | 2005-11-02 | 2007-06-28 | Tetsuya Gatanaga | Native TRRE: protein implicated in TNF receptor shedding for treating arthritis and inflammation |
| CN101460851B (zh) * | 2006-03-13 | 2016-09-21 | 贝克顿·迪金森公司 | 与二肽基肽酶有关的疾病状态的诊断和预后 |
| CA2659082A1 (en) | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| ATE527353T1 (de) | 2007-12-19 | 2011-10-15 | Affibody Ab | Pdgf-bindendes polypeptid aus protein a |
| MX359570B (es) | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| WO2010093872A2 (en) * | 2009-02-13 | 2010-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
| BR112012004314A2 (pt) | 2009-08-27 | 2016-11-29 | Covagen Ag | compostos de ligação a il-17 e usos medicinais desses compostos |
| KR101436222B1 (ko) | 2009-12-14 | 2014-09-01 | 쉴 프로테인즈 게엠베하 | 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법 |
| KR101234352B1 (ko) * | 2010-03-18 | 2013-02-15 | 권동락 | 선택적 면역 세포 분리 반출장치 |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| CN104946646B (zh) * | 2014-03-25 | 2020-03-31 | 中国医学科学院基础医学研究所 | 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用 |
| MY200300A (en) * | 2016-04-21 | 2023-12-19 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and therapeutic methods |
-
2017
- 2017-04-20 MY MYPI2018703855A patent/MY200300A/en unknown
- 2017-04-20 CH CH001280/2018A patent/CH713803B1/de unknown
- 2017-04-20 WO PCT/EP2017/059377 patent/WO2017182561A1/en not_active Ceased
- 2017-04-20 IL IL262472A patent/IL262472B2/en unknown
- 2017-04-20 EP EP21153560.4A patent/EP3896450A1/en active Pending
- 2017-04-20 EP EP21153574.5A patent/EP3854817A1/en active Pending
- 2017-04-20 CN CN201780039077.1A patent/CN110168372A/zh active Pending
- 2017-04-20 US US16/095,563 patent/US20190145981A1/en active Pending
- 2017-04-20 EP EP17720047.4A patent/EP3446125B1/en active Active
- 2017-04-20 BR BR112018071583-2A patent/BR112018071583A2/pt unknown
- 2017-04-20 CA CA3264486A patent/CA3264486A1/en active Pending
- 2017-04-20 KR KR1020237026743A patent/KR102886883B1/ko active Active
- 2017-04-20 CN CN202510254123.6A patent/CN120093910A/zh active Pending
- 2017-04-20 EP EP24178574.0A patent/EP4417218A3/en active Pending
- 2017-04-20 CA CA3021252A patent/CA3021252A1/en active Pending
- 2017-04-20 AU AU2017252212A patent/AU2017252212B2/en active Active
- 2017-04-20 SG SG11201809252YA patent/SG11201809252YA/en unknown
- 2017-04-20 MX MX2018012856A patent/MX2018012856A/es unknown
- 2017-04-20 KR KR1020187033194A patent/KR102565453B1/ko active Active
- 2017-04-20 DE DE112017002105.7T patent/DE112017002105T5/de active Pending
- 2017-04-20 CN CN202511191873.XA patent/CN120992960A/zh active Pending
- 2017-04-20 KR KR1020247025458A patent/KR102886863B1/ko active Active
- 2017-04-20 EP EP24178565.8A patent/EP4417217A3/en active Pending
- 2017-04-20 JP JP2018555652A patent/JP2019520550A/ja active Pending
-
2018
- 2018-10-19 MX MX2025006655A patent/MX2025006655A/es unknown
- 2018-10-19 MX MX2020001193A patent/MX2020001193A/es unknown
-
2020
- 2020-04-23 JP JP2020076521A patent/JP7219737B2/ja active Active
- 2020-07-02 US US16/919,449 patent/US11726094B2/en active Active
-
2022
- 2022-07-08 JP JP2022110620A patent/JP2022163014A/ja active Pending
-
2023
- 2023-06-21 US US18/338,805 patent/US20240385197A1/en active Pending
- 2023-11-02 AU AU2023258417A patent/AU2023258417B2/en active Active
-
2024
- 2024-10-11 JP JP2024178873A patent/JP2025011237A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017113019A5 (enExample) | ||
| JP2008523083A5 (enExample) | ||
| Meyer et al. | Rheumatoid arthritis and risk of cardiovascular disease | |
| Auerbach et al. | Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor | |
| Doi et al. | Role of vascular endothelial growth factor in kidney disease | |
| Anliker-Ort et al. | Treatment of rare inflammatory kidney diseases: drugs targeting the terminal complement pathway | |
| Eppensteiner et al. | Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults | |
| Su et al. | HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion | |
| Chatterjee et al. | SDF‐1α induces differential trafficking of CXCR4‐CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival | |
| EA201200795A1 (ru) | Связывающие элементы для пептида с5а с высоким ингибирующим действием | |
| Chatterjee et al. | Inflammatory contribution of platelets revisited: new players in the arena of inflammation | |
| JP2014518883A5 (enExample) | ||
| JP2016183160A5 (enExample) | ||
| Steckelings et al. | Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists | |
| IL262472B1 (en) | Dpp3 inhibitors for use in treating diseases related to necrosis | |
| JP2011503012A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2019506159A5 (enExample) | ||
| JP2011184466A5 (enExample) | ||
| JP2020503345A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| JP2016529229A5 (enExample) | ||
| FI3553084T3 (fi) | Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa | |
| JP2018534250A (ja) | アネキシンｖの製造プロセス |